Sequential parallel comparison design (SPCD) was proposed to reduce placebo response in a randomized trial with placebo comparator. Subjects are randomized between placebo and drug in stage 1 of the trial, and then, placebo non-responders are re-randomized in stage 2. Efficacy analysis includes all data from stage 1 and all placebo non-responding subjects from stage 2. This article investigates the possibility to re-estimate the sample size and adjust the design parameters, allocation proportion to placebo in stage 1 of SPCD, and weight of stage 1 data in the overall efficacy test statistic during an interim analysis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10543406.2017.1289951 | DOI Listing |
Publication Analysis
Top Keywords
sample size
8
sequential parallel
8
parallel comparison
8
comparison design
8
trial placebo
8
placebo
6
stage
6
size re-estimation
4
re-estimation midcourse
4
midcourse adjustments
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!